StrokeNCT02325427
Changes in Brain Activity Associated With Upper Limb Motor Recovery
A study testing tDCS in people with Stroke, run by National University Hospital, Singapore at 1 site in Singapore.
Trial summary
This study is to investigate changes in brain activities in acute stroke patients , and to correlate findings with clinical outcome measures. Another aim of the study is to investigate whether transcranial direct current stimulation (tDCS) could improve motor function in subjects with poor brain activity after stroke. Read more about this study
- Who is it for?
- Ages 21 to 80 years
- Conditions the study is for
- Stroke
- What is being tested?
- tDCS
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 8 participants
- Where
- 1 siteSingapore
- Study dates
- Nov 2014to Jul 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female aged 21-80 years;
- First ever haemorrhagic or ischaemic hemiplegic stroke less than 1 month prior to study enrollment;
- Upper extremity impairment of 0-45 out of a maximum score of 66 on the Fugl-Meyer assessment scale.
- MMSE>=24.
- Be able to provide informed consent.
Who cannot join
- pregnancy; cardiac pacemakers; orthodontics (braces); metal implant; history of epilepsy; sensorimotor disturbance due to other causes other than stroke; uncontrolled medical conditions including hypertension, diabetes mellitus and unstable angina; major depression and a history of psychotic disorders.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Changes in Cortical Excitability Associated With Upper Limb Motor Recovery - a Study of Neural Strategies Employed in Motor Recovery
This study is to investigate changes in brain activities in acute stroke patients , and to correlate findings with clinical outcome measures. Another aim of the study is to investigate whether transcranial direct current stimulation (tDCS) could improve motor function in subjects with poor brain activity after stroke. The brain activity will be measured by single and paired pulse TMS (transcranial magnetic stimulation). The study hypothesizes that:
- The neural mechanisms employed in patients who have different response to TMS stimulation are different. It is hypothesized that patients with no response upon TMS stimulation might have poorer motor function outcome, compared with patients with response upon TMS stimulation.
- The result of clinical outcome measures is related with TMS measurement.
- tDCS intervention is beneficial to subjects with poor brain activity. Clinical outcome measures will include a battery of upper limb motor tests such as upper extremity component of the Fugl-Meyer Assessment, Modified Ashworth scale for spasticity, box and block test, and manual muscle testing. Clinical outcome and TMS measurement will be assessed at within 2 weeks, 4-6 weeks and at 6 months post-stroke.
Read the detailed description
TMS measurement and clinical outcome measurement will be performed on 119 stroke subjects with upper limb impairment with FMA score at 0-45 at within 1 month from stroke, 6-8 weeks post-stroke, 6 months post-stroke. It is important to know the cortical excitability as well as clinical outcome measurement at the same time point, at different stages of stroke including acute phase, which enables us to know the interaction between brain activity and functional outcome. In addition, studies have shown both TMS (Pennisi et al, 1999) and clinical outcome measurement (FMA)(De Weerdt and Harrison 1985; Bernspang et al. 1987; Feys et al. 2000) are measurable at acute phase after stroke.
Subjects will be recruited from the existing patients on the study physician's cohort of patients and from referrals from attending physicians. During the initial screening visit, FMA will be administered by trained research staff, the questionnaire of MMSE will also be administered by trained research staff for subject's cognitive assessment. Subjects' eligibility will be verified by self-report from the participants as well as their medical records accessed by participating physicians. It will be ascertained that subject fulfills criteria for participation and informed consent will be obtained by study staff. Subjects will be fully briefed in detail regarding the experimental procedure, risk and benefits involved and their responsibilities during the study. Subject will continue with their routine rehabilitation training when they are in the trial.
For patients whose MEP could not be induced by single pulse TMS stimulation, they will be randomly divided into 2 groups with one group receiving 1mA tDCS stimulation for 20 minutes to the primary motor cortex of cortical representation of the hand, while the other group will receive sham stimulation of tDCS.
A research staff supervised by a physician will apply the tDCS to subjects whose MEP could not be induced by TMS stimulation to the corresponding cortex area. Direct current will be transferred by a saline-soaked pair of surface sponge electrode (35cm2) and delivered by a battery-operated, constant current stimulator with a maximum output of 10mA, through a non-metallic conductor rubber electrode. Stimulation will be conducted at the intensity of 1 mA and last for 20 minutes. The anode will be placed over the affected primary motor cortex (M1) of cortical representation of the hand, while the cathode will be used as reference electrode and placed over the forehead of the unaffected side. The same stimulation parameters as tDCS treatment will be employed for the sham stimulation. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation. Current intensity will be increased and decreased gradually (0-1mA) to decrease perception. It is postulated to recruit 20 subjects for each intervention group. The real or sham tDCS intervention will be conducted daily for 10 days after the first and before the second TMS assessment, i.e., between 2 to 6 weeks after the stroke onset. And the real or sham tDCS will be conducted before the daily traditional rehabilitation training, if any.
A research staff supervised by a physician will apply TMS measurement of the cortical excitability and intracortical inhibition/facilitation to the subject. Patients will be seated comfortably and instructed to remain as still as they can. A tight swim cap will be worn by the subject. The vertex will be marked on the cap. Singe pulse TMS was delivered using Magstim Bistim² stimulator via the coil of figure of eight. The coil position was maintained manually by an assistant and the handle of the coil point to posterior with an angel of 45 degree to the sagittal plane. Surface electromyography (EMG) electrodes are attached to the abductor pollicis brevis muscle (APB) for EMG recording. The "hot spot" of the motor evoked potential (MEP) from APB is first identified and marked for both left and right side. This spot will be used for all recordings on that side. The lowest intensity needed to elicit a MEP response of at least 50µV amplitude and that has been elicited in 50% of 8 successive trials will be recorded as resting motor threshold (RMT).
For intracortical inhibition/facilitation recording, a first subthreshold conditioning stimulus (80% of RMT) will be applied, followed by a second suprathreshold stimulus (120% of RMT) with a variable interstimulus interval (ISI). The following ISIs - 2, 3, 4, 6, 9, 10, 12, 15 ms will be used. The percentage of change for each ISI before and after TMS will be calculated from the MEPs and will therefore provide a measure of change in intracortical facilitation and inhibition. Both single- and paired-pulse paradigms will be performed on the affected and unaffected hemisphere.
Clinical outcome measurement includes a battery of upper limb motor tests: Fugl-Meyer Assessment, Modified Ashworth scale for spasticity, manual muscle testing and box and block test, which will be performed by a trained research staff.
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
tDCSDevice
tDCS could deliver either real or sham stimulation.
| Study group | Role | What they receive |
|---|---|---|
| real tDCS | Experimental | Subjects will receive tDCS stimulation at the intensity of 1 mA and last for 20 minutes. The anode will be placed over the affected primary motor cortex (M1) of cortical representation of the hand, while the cathode will be used as reference electrode and placed over the forehead of the unaffected side. Receives: Device: tDCS |
| sham tDCS | Sham comparator | Subjects will receive sham tDCS stimulation. The same stimulation parameters as tDCS treatment will be employed for the sham stimulation. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation. Receives: Device: tDCS |
| no stimulation | No intervention | Subjects will not received any intervention. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change of TMS (transcranial magnetic stimulation) measurement of cortical excitability
Measured: within 1 month from stroke, 6-8 weeks post-stroke, 6 months post-stroke
Secondary outcomes (4)
Change of upper limb motor function in terms of Modified Ashworth scale for spasticity
Measured: within 1 month from stroke, 6-8 weeks post-stroke, 6 months post-stroke
Change of upper limb motor function in terms of Manual muscle testing
Measured: within 1 month from stroke, 6-8 weeks post-stroke, 6 months post-stroke
Change of upper limb motor function in terms of Box and block test
Measured: within 1 month from stroke, 6-8 weeks post-stroke, 6 months post-stroke
Change of upper limb motor function in terms of Fugl-Meyer Assessment
Measured: within 1 month from stroke, 6-8 weeks post-stroke, 6 months post-stroke
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Dec 2014 (estimated)
- Study startNov 2014
- Primary completionJul 2020
- Study completionJul 2020
Why it stopped: short of funding support.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for StrokeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 8 participants (actual)
Sponsor and investigators
- Lead sponsor
- National University Hospital, Singapore
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Effie Chew, MD, Principal investigator, National University Hospital, Singapore
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02325427
- Sponsor's protocol ID
- TMS2014/00358
- Status last verified
- Apr 2022
- First submitted
- 21 Dec 2014
- Last updated
- 22 Apr 2022
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- Undecided
Publications
Elsner B, Kugler J, Pohl M, Mehrholz J. Transcranial direct current stimulation (tDCS) for improving activities of daily living, and physical and cognitive functioning, in people after stroke. Cochrane Database Syst Rev. 2020 Nov 11;11(11):CD009645. doi: 10.1002/14651858.CD009645.pub4.
PubMed 33175411
Study at a glance
From the registry record, last updated by the sponsor on 22 Apr 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Changes in Cortical Excitability Associated With Upper Limb Motor Recovery - a Study of Neural Strategies Employed in Motor Recovery
- ClinicalTrials.gov ID
- NCT02325427
- Acronym / sponsor ID
- TMS2014/00358
- Conditions
- Stroke
- Keywords
- stroke, rehabilitation, upper limb, TMS, tDCS
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: short of funding support.
- Enrolment
- 8 participants (actual)
- Lead sponsor
- National University Hospital, SingaporeUniversity, hospital or other
- Study start
- Nov 2014 (actual)
- Primary completion
- Jul 2020 (actual)
- Study completion
- Jul 2020 (actual)
- First posted
- 25 Dec 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is to investigate changes in brain activities in acute stroke patients , and to correlate findings with clinical outcome measures. Another aim of the study is to investigate whether transcranial direct current stimulation (tDCS) could improve motor function in subjects with poor brain activity after stroke. The brain activity will be measured by single and paired pulse TMS (transcranial magnetic stimulation). The study hypothesizes that:
- The neural mechanisms employed in patients who have different response to TMS stimulation are different. It is hypothesized that patients with no response upon TMS stimulation might have poorer motor function outcome, compared with patients with response upon TMS stimulation.
- The result of clinical outcome measures is related with TMS measurement.
- tDCS intervention is beneficial to subjects with poor brain activity. Clinical outcome measures will include a battery of upper limb motor tests such as upper extremity component of the Fugl-Meyer Assessment, Modified Ashworth scale for spasticity, box and block test, and manual muscle testing. Clinical outcome and TMS measurement will be assessed at within 2 weeks, 4-6 weeks and at 6 months post-stroke.
Detailed description
TMS measurement and clinical outcome measurement will be performed on 119 stroke subjects with upper limb impairment with FMA score at 0-45 at within 1 month from stroke, 6-8 weeks post-stroke, 6 months post-stroke. It is important to know the cortical excitability as well as clinical outcome measurement at the same time point, at different stages of stroke including acute phase, which enables us to know the interaction between brain activity and functional outcome. In addition, studies have shown both TMS (Pennisi et al, 1999) and clinical outcome measurement (FMA)(De Weerdt and Harrison 1985; Bernspang et al. 1987; Feys et al. 2000) are measurable at acute phase after stroke.
Subjects will be recruited from the existing patients on the study physician's cohort of patients and from referrals from attending physicians. During the initial screening visit, FMA will be administered by trained research staff, the questionnaire of MMSE will also be administered by trained research staff for subject's cognitive assessment. Subjects' eligibility will be verified by self-report from the participants as well as their medical records accessed by participating physicians. It will be ascertained that subject fulfills criteria for participation and informed consent will be obtained by study staff. Subjects will be fully briefed in detail regarding the experimental procedure, risk and benefits involved and their responsibilities during the study. Subject will continue with their routine rehabilitation training when they are in the trial.
For patients whose MEP could not be induced by single pulse TMS stimulation, they will be randomly divided into 2 groups with one group receiving 1mA tDCS stimulation for 20 minutes to the primary motor cortex of cortical representation of the hand, while the other group will receive sham stimulation of tDCS.
A research staff supervised by a physician will apply the tDCS to subjects whose MEP could not be induced by TMS stimulation to the corresponding cortex area. Direct current will be transferred by a saline-soaked pair of surface sponge electrode (35cm2) and delivered by a battery-operated, constant current stimulator with a maximum output of 10mA, through a non-metallic conductor rubber electrode. Stimulation will be conducted at the intensity of 1 mA and last for 20 minutes. The anode will be placed over the affected primary motor cortex (M1) of cortical representation of the hand, while the cathode will be used as reference electrode and placed over the forehead of the unaffected side. The same stimulation parameters as tDCS treatment will be employed for the sham stimulation. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation. Current intensity will be increased and decreased gradually (0-1mA) to decrease perception. It is postulated to recruit 20 subjects for each intervention group. The real or sham tDCS intervention will be conducted daily for 10 days after the first and before the second TMS assessment, i.e., between 2 to 6 weeks after the stroke onset. And the real or sham tDCS will be conducted before the daily traditional rehabilitation training, if any.
A research staff supervised by a physician will apply TMS measurement of the cortical excitability and intracortical inhibition/facilitation to the subject. Patients will be seated comfortably and instructed to remain as still as they can. A tight swim cap will be worn by the subject. The vertex will be marked on the cap. Singe pulse TMS was delivered using Magstim Bistim² stimulator via the coil of figure of eight. The coil position was maintained manually by an assistant and the handle of the coil point to posterior with an angel of 45 degree to the sagittal plane. Surface electromyography (EMG) electrodes are attached to the abductor pollicis brevis muscle (APB) for EMG recording. The "hot spot" of the motor evoked potential (MEP) from APB is first identified and marked for both left and right side. This spot will be used for all recordings on that side. The lowest intensity needed to elicit a MEP response of at least 50µV amplitude and that has been elicited in 50% of 8 successive trials will be recorded as resting motor threshold (RMT).
For intracortical inhibition/facilitation recording, a first subthreshold conditioning stimulus (80% of RMT) will be applied, followed by a second suprathreshold stimulus (120% of RMT) with a variable interstimulus interval (ISI). The following ISIs - 2, 3, 4, 6, 9, 10, 12, 15 ms will be used. The percentage of change for each ISI before and after TMS will be calculated from the MEPs and will therefore provide a measure of change in intracortical facilitation and inhibition. Both single- and paired-pulse paradigms will be performed on the affected and unaffected hemisphere.
Clinical outcome measurement includes a battery of upper limb motor tests: Fugl-Meyer Assessment, Modified Ashworth scale for spasticity, manual muscle testing and box and block test, which will be performed by a trained research staff.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| real tDCS | Experimental | Device: tDCSSubjects will receive tDCS stimulation at the intensity of 1 mA and last for 20 minutes. The anode will be placed over the affected primary motor cortex (M1) of cortical representation of the hand, while the cathode will be used as reference electrode and placed over the forehead of the unaffected side. |
| sham tDCS | Sham comparator | Device: tDCSSubjects will receive sham tDCS stimulation. The same stimulation parameters as tDCS treatment will be employed for the sham stimulation. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation. |
| no stimulation | No intervention | –Subjects will not received any intervention. |
Who may qualify
- Ages
- 21 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Male or female aged 21-80 years;
- First ever haemorrhagic or ischaemic hemiplegic stroke less than 1 month prior to study enrollment;
- Upper extremity impairment of 0-45 out of a maximum score of 66 on the Fugl-Meyer assessment scale.
- MMSE>=24.
- Be able to provide informed consent.
Key exclusion criteria (1 listed)
- pregnancy; cardiac pacemakers; orthodontics (braces); metal implant; history of epilepsy; sensorimotor disturbance due to other causes other than stroke; uncontrolled medical conditions including hypertension, diabetes mellitus and unstable angina; major depression and a history of psychotic disorders.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| tDCStDCS could deliver either real or sham stimulation. | Device | real tDCS, sham tDCS |
Primary outcome
Change of TMS (transcranial magnetic stimulation) measurement of cortical excitability
Time frame: within 1 month from stroke, 6-8 weeks post-stroke, 6 months post-stroke
4 secondary outcomes
Change of upper limb motor function in terms of Modified Ashworth scale for spasticity
Time frame: within 1 month from stroke, 6-8 weeks post-stroke, 6 months post-stroke
Change of upper limb motor function in terms of Manual muscle testing
Time frame: within 1 month from stroke, 6-8 weeks post-stroke, 6 months post-stroke
Change of upper limb motor function in terms of Box and block test
Time frame: within 1 month from stroke, 6-8 weeks post-stroke, 6 months post-stroke
Change of upper limb motor function in terms of Fugl-Meyer Assessment
Time frame: within 1 month from stroke, 6-8 weeks post-stroke, 6 months post-stroke
Results and safety
The study was stopped early (reason given: short of funding support.). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Apr 2022.
- Derived from this study: PubMed 33175411Elsner B, Kugler J, Pohl M, Mehrholz J. Transcranial direct current stimulation (tDCS) for improving activities of daily living, and physical and cognitive functioning, in people after stroke. Cochrane Database Syst Rev. 2020 Nov 11;11(11):CD009645. doi: 10.1002/14651858.CD009645.pub4.
- Individual participant dataSharing planned: Undecided
Related trials for Stroke
Recruiting
Connectomic Alterations Following Acute Ischemic Stroke in the MCA Territory
Ischemic Stroke
RecruitingObservational study
Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage
Intracerebral Hemorrhage, Stroke
Active, not recruitingPhase 4
A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment
Ischemic Stroke Hospitalized, Impairment, Cognitive
Not yet recruitingPhase 4
Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke
Ischemic Stroke
RecruitingObservational study
CoMind Early Feasibility Study
Intracranial Pressure, Intracranial Pressure Changes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Effie Chew, MD principal investigator
National University Hospital, Singapore
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing tDCS in people with Stroke, run by National University Hospital, Singapore at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 22 Apr 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: short of funding support.). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change of TMS (transcranial magnetic stimulation) measurement of cortical excitability (time frame: within 1 month from stroke, 6-8 weeks post-stroke, 6 months post-stroke). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02325427, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Apr 2022.